Combination therapy showed no clear difference in adverse events compared with alpha‐blockers (low certainty).
Combination therapy showed no clear difference in AUR compared with alpha‐blockers (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + DPP4‐I compared with metformin plus another antidiabetic drug (very low certainty).
It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + thiazolidinedione compared with metformin plus another antidiabetic drug (very low certainty).
It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + SGLT2‐I compared with metformin plus another antidiabetic drug (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether combination chemotherapy changes overall survival (3 years) compared with single‐agent chemotherapy (very low certainty).
It is very uncertain whether combination chemotherapy changes disease‐free survival (3 years) compared with single‐agent chemotherapy (very low certainty).
Combination chemotherapy leads to higher complete response rate after preoperative chemoradiation (ypCR) compared with single‐agent chemotherapy (high certainty).
Combination chemotherapy probably leads to higher toxicity ‐ early adverse events G3/4 compared with single‐agent chemotherapy (moderate certainty).
Combination chemotherapy showed no clear difference in metastases intra‐abdominal compared with single‐agent chemotherapy (moderate certainty).
Gemcitabine combinations may leads to lower overall survival ‐ Gemcitabine plus other combinations of chemotherapy compared with gemcitabine alone (low certainty).
Monotherapy showed no clear difference in all‐cause mortality—same beta lactam Survival compared with combination therapy compared (low certainty).
Monotherapy showed no clear difference in all‐cause mortality—different beta lactam compared with combination therapy compared (low certainty).
It is very uncertain whether monotherapy changes clinical failure—same beta lactam Antibiotic modifications compared with combination therapy compared (very low certainty).
It is very uncertain whether monotherapy changes clinical failure—different beta lactam Antibiotic modifications compared with combination therapy compared (very low certainty).